UB Paderborn / Katalog / Suche / in CDI

The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model

Human reproduction (Oxford), 2021-08, Vol.36 (9), p.2514-2528

2021

Link zum Volltext

Verfügbarkeit prüfen

Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling

Gene therapy, 2006-01, Vol.13 (1), p.8-19

2006

Link zum Volltext

Verfügbarkeit prüfen

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial

Annals of oncology, 2015-04, Vol.26 (4), p.675-682

2015

Link zum Volltext

Verfügbarkeit prüfen

The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid

Annals of oncology, 2018-10, Vol.29, p.viii704-viii704

2018

Link zum Volltext

Verfügbarkeit prüfen

PerTe: efficacy and safety of pertuzumab in "real life setting" for the neoadjuvant treatment of HER2-positive breast cancer patients

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi36

2017

Link zum Volltext

Verfügbarkeit prüfen

High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients

European review for medical and pharmacological sciences, 2017-07, Vol.21 (13), p.3134

2017

Link zum Volltext

Verfügbarkeit prüfen

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

Annals of oncology, 2012-08, Vol.23 (8), p.2027-2033

2012

Link zum Volltext

Verfügbarkeit prüfen

O-265 Luteinizing hormone is able to protect reproductive health in cancer patients

Human reproduction (Oxford), 2022-06, Vol.37 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

449P Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study

Annals of oncology, 2023-10, Vol.34, p.S370-S370

2023

Link zum Volltext

Verfügbarkeit prüfen

Bone mineral density and circulating cytokines in patients with acromegaly

Journal of endocrinological investigation, 1998-11, Vol.21 (10), p.688-693

1998

Link zum Volltext

Verfügbarkeit prüfen

Weekly Docetaxel (Wd) Vs Cmf As Adjuvant Chemotherapy for Elderly Early Breast Cancer (Ebc) Patients (Pts): Final Results from the Randomised Phase 3 Elda Trial

Annals of oncology, 2014-09, Vol.25, p.iv86

2014

Link zum Volltext

Verfügbarkeit prüfen

2050 POSTER Endocrine effects of adjuvant letrozole plus triptoreline versus tamoxifen plus triptoreline in premenopausal patients with early breast cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.199-199

2007

Link zum Volltext

Verfügbarkeit prüfen

Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients

Journal of endocrinological investigation, 1999-05, Vol.22 (5), p.333-339

1999

Link zum Volltext

Verfügbarkeit prüfen

An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients

In vivo (Athens), 2023-07, Vol.37 (4), p.1445-1449

2023

Link zum Volltext

Verfügbarkeit prüfen

Differential expression of TNF-alpha , IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium

American journal of physiology. Heart and circulatory physiology, 2002-03, Vol.282 (3), p.H926-H934

2002

Link zum Volltext

Verfügbarkeit prüfen

Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.517-517

2011

Link zum Volltext

Verfügbarkeit prüfen

Abnormal vascular reactivity in growth hormone deficiency

Circulation (New York, N.Y.), 2001-01, Vol.103 (4), p.520-524

2001

Link zum Volltext

Verfügbarkeit prüfen

Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency

Clinical endocrinology (Oxford), 1998-02, Vol.48 (2), p.137-144

1998

Link zum Volltext

Verfügbarkeit prüfen

Endocrine effects of adjuvant letrozole versus tamoxifen in hormone responsive postmenopausal early breast cancer patients: results from the HOBOE randomized trial

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.1150

2009

Link zum Volltext

Verfügbarkeit prüfen

Endocrine effects of letrozole + triptoreline compared to tamoxifen + triptoreline as adjuvant treatment of premenopausal patients with early breast cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.578-578

2007

Link zum Volltext

Verfügbarkeit prüfen

LBA14_PRThe HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

Annals of oncology, 2012-08, Vol.23 (8), p.2027

2012

Link zum Volltext

Verfügbarkeit prüfen

Growth hormone- and pressure overload-induced cardiac hypertrophy evoke different responses to ischemia-reperfusion and mechanical stretch

Growth hormone & IGF research, 2006-02, Vol.16 (1), p.29-40

2006

Link zum Volltext

Verfügbarkeit prüfen

5047 Effects on quality of life (QoL) of docetaxel-based weekly chemotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC): results of a single-centre randomized phase 3 trial

European journal of cancer supplements, 2009, Vol.7 (2), p.274-275

2009

Link zum Volltext

Verfügbarkeit prüfen

256OWEEKLY DOCETAXEL (WD) VS CMF AS ADJUVANT CHEMOTHERAPY FOR ELDERLY EARLY BREAST CANCER (EBC) PATIENTS (PTS): FINAL RESULTS FROM THE RANDOMISED PHASE 3 ELDA TRIAL

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv86-iv86

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model

Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial

The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid

PerTe: efficacy and safety of pertuzumab in "real life setting" for the neoadjuvant treatment of HER2-positive breast cancer patients

High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

O-265 Luteinizing hormone is able to protect reproductive health in cancer patients

449P Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study

Bone mineral density and circulating cytokines in patients with acromegaly

Weekly Docetaxel (Wd) Vs Cmf As Adjuvant Chemotherapy for Elderly Early Breast Cancer (Ebc) Patients (Pts): Final Results from the Randomised Phase 3 Elda Trial

2050 POSTER Endocrine effects of adjuvant letrozole plus triptoreline versus tamoxifen plus triptoreline in premenopausal patients with early breast cancer

Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients

An Overview of the Roles of CDK4/6 Inhibitors in Metastatic Breast Cancer Elderly Patients

Differential expression of TNF-alpha , IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium

Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBOE study

Abnormal vascular reactivity in growth hormone deficiency

Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency

Endocrine effects of adjuvant letrozole versus tamoxifen in hormone responsive postmenopausal early breast cancer patients: results from the HOBOE randomized trial

Endocrine effects of letrozole + triptoreline compared to tamoxifen + triptoreline as adjuvant treatment of premenopausal patients with early breast cancer

LBA14_PRThe HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

Growth hormone- and pressure overload-induced cardiac hypertrophy evoke different responses to ischemia-reperfusion and mechanical stretch

5047 Effects on quality of life (QoL) of docetaxel-based weekly chemotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC): results of a single-centre randomized phase 3 trial

256OWEEKLY DOCETAXEL (WD) VS CMF AS ADJUVANT CHEMOTHERAPY FOR ELDERLY EARLY BREAST CANCER (EBC) PATIENTS (PTS): FINAL RESULTS FROM THE RANDOMISED PHASE 3 ELDA TRIAL

Suchergebnisse filtern